This week, the Hang Seng Index fell 6.41% to close at 22767.18.

This week, there are a total of 9 IPOs, 1 IPO, 1 IPO and 1 IPO.

Intelligent fitness platform Keep presents the Hong Kong Stock Exchange. In 2021, Keep is the largest online fitness platform in China and the world in terms of the number of monthly active users and the number of exercise completed by users.

This week, the watch delivery company also has well-known Chinese fast food brands.Yang GuofuEnterprise artificial intelligence software industry leading companyThe fourth paradigmInnovative Heart Valve equipment Co., Ltd.New pulse medical treatmentAnd special purpose acquisition companies.Vivere Lifesciences等。

KeepOfficially launched in 2015, a comprehensive fitness solution has been developed, covering the entire fitness life cycle of Keeper ("Keep users"). The company's products include online fitness content, intelligent fitness equipment and supporting sports products. According to the cautionary report, Keep is the largest online fitness platform in China and the world in terms of the number of monthly active users and the number of exercises completed by users in 2021.

In 2020 and 2021, the average monthly active users of the company's platform were 29.7 million and 34.4 million, respectively. In 2021, Keeper recorded a total of about 1.7 billion exercises on the company's platform.

Yang GuofuIt is a well-known Chinese fast food brand. As of September 30, 2021, the company's "Yang Guofu" brand has a total of 5783 restaurants, including 3 self-owned restaurants in Shanghai and 5759 franchised restaurants in 31 provinces and cities in China. and 21 overseas franchised restaurants in Australia, Canada, South Korea, the United States, Japan and Singapore. According to Frost Sullivan, Yang Guofu ranked first in China's Spicy Hot Pot market and China's Chinese fast food market in terms of total merchandise transactions and the number of restaurants in 2020.

The fourth paradigmFocus on providing platform-centric artificial intelligence solutions to enable enterprises to achieve rapid large-scale transformation of artificial intelligence, explore hidden rules of data and comprehensively improve the decision-making ability of enterprises. According to the cautionary report, the company has the largest market share in China's platform-centric artificial intelligence market in terms of revenue in 2020. The automatic machine learning algorithm developed by the company is one of the most cutting-edge automatic machine learning algorithms in the world.

New pulse medical treatmentIs an innovative heart valve device company that has established a comprehensive product portfolio covering one core product and eight other valvular products under development, including transcatheter replacement and repair products for the treatment of human heart valves, and seven assistive devices for interventional heart surgery. As of February 16, 2022, the company's core product, Prizvalve ®, a ball-expanded transcatheter aortic valve replacement product, is undergoing confirmatory clinical trials.

Vivere Lifesciences AcquisitionIs a special purpose acquisition company established to conduct a special purpose acquisition transaction, the company will focus more on China or other global healthcare industries with a Chinese perspective, with a particular focus on biotechnology, diagnostics, medical professional equipment, new platform technologies and healthcare related technologies, synthetic biology and CXO.

The sponsors of the company are Dingyi Asset Management, I-MAB, Mr. Wu Zhaowei, Mr. Zhu Jielun and Dr. Chen Yajun.

Think of school healthStarting from the medical network built by SMO, building special medicine pharmacies, and then further opening up commercial insurance payments, so as to establish a closed loop of "medical and health insurance services". The three business lines of Sippai Health are: doctor Research solution (PRS), Drug benefit Management (PBM) and supplier and payment solution (PPS). In terms of 2020 annual revenue, the company's PRS operates the largest oncology clinical trial site management organization ("SMO"), while the company's PBM operates the largest private specialty pharmacy.

Gramineous organismCommitted to developing and providing innovative interventional medical devices for patients, the company has established a full range of innovative interventional medical devices for peripheral and neurovascular diseases in China and other parts of the Asia-Pacific region. As of the last practical date, Wo Mu Bio has 6 commercial products that have generated revenue, and the products have been used in 306 hospitals in 24 provinces and cities in China. 14 kinds of products under development are in the stage of development, including 6 kinds of products under development are in the stage of registration review or clinical trials, and 8 kinds of products in research are in the preclinical stage.

Hongxin constructionThe main brands include Hongxin Jianfa, Hongxin equipment and Hongjin equipment. According to the Frost Sullivan report, the company is the largest equipment operation service provider in China in terms of 2020 revenue. Benefiting from its leading position in the industry, the company is able to participate in domestic milestone projects, such as Shanghai National Exhibition and Convention Center project, Beijing Daxing International Airport project, Hong Kong-Zhuhai-Macao Bridge project and Huoshenshan Hospital project.

Neusoft XikangIs one of the pioneers in China's new medical services market, creating China's first city-based cloud hospital platform and establishing a cloud hospital network that connects policy makers, medical institutions, patients and insurance companies in the city. As of December 31, 2021, the company's network includes cloud hospital platforms with cities as entrances in 28 cities in China. According to Frost Sullivan, as of December 31, 2020, the company is the largest cloud hospital network in China in terms of the number of cities covered.

Yunkang GroupIs a medical operational service provider in China, providing a full range of diagnostic testing services for medical institutions, with a 3.7% market share in China's medical operational services market by revenue in 2020. As of 2018, December 31, 2020 and February 15, 2022, the company has assisted in the establishment and operation of 79, 199 and 301 on-site diagnostic centers. In 2020, according to Frost Sullivan, the company's market share of diagnostic testing services in China was 12.5% in terms of revenue.

There is only one new offering this week.

$Jinmao Service (00816.HK) $In its initial public offering from February 25 to March 2, the company plans to issue about 101 million shares, including a public offering of 10.142 million shares and an international offering of 91.2695 million shares at an issue price of HK $7.52 to HK $8.14 per share.

As of press time, the margin margin of Jinmao service has reached 0.23 times, with a financing subscription of HK $19.2 million.

Only one new stock went public this week.

$Lepu Biology-B (02157.HK) $It rose 0.14% on the first day and closed up 0.14% at HK $7.13 as of Friday.